BCL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Accordingly, BCL6 targeting has been demonstrated to eradicate CML stem cells in patient-derived samples, thus highlighting the possibility to target BCL6 to circumvent CML stem cell-dependent TKI resistance [146].